Vicagrel

Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. In Vitro Vicagrel (compound 9a) (20 μM, 30 min) activates production of the active metabolite from in vitro rat liver microsomal. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Vicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats . Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose . Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (200−250 g) Dosage: 3 mg/kg Administration: oral Result: Inhibitied platelet aggregation by ADP-induced in rats. Animal Model: SD male rats Dosage: 1.14 mg/mL Administration: oral, 0-24 h Result: Could be readily converted into clopidogrel thiolactone and had high bioavailability. Animal Model: Mice Dosage: 5 g/kg Administration: oral, single, for 14 days Result: Had very low acute toxicity.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet